GRAL
GRAIL, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$122.42
+3.91%Year over year
Reported trailing growth
- Revenue
- +23.1%
- EBITDA
- +15.1%
- EBIT
- +11.6%
- EPS
- +25.6%
- Free cash flow
- +20.6%
- Operating cash flow
- +20.3%
Forward estimates
Based on analyst estimates
- Revenue
- +28.0%
- EBITDA
- +14.5%
- EPS
- -9.3%
Three-year CAGR
- Revenue
- +38.4%
- EBITDA
- +38.0%
- EBIT
- +75.6%
- Net income
- +79.9%
- EPS
- +82.5%
- Free cash flow
- +48.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026